Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) FCF Margin (2016 - 2024)

Capricor Therapeutics has reported FCF Margin over the past 14 years, most recently at 137.33% for Q4 2024.

  • For Q4 2024, FCF Margin fell 3679.0% year-over-year to 137.33%; the TTM value through Dec 2025 reached 653.3%, down 50287.0%, while the annual FY2024 figure was 184.83%, 7796.0% down from the prior year.
  • FCF Margin for Q4 2024 was 137.33% at Capricor Therapeutics, up from 515.18% in the prior quarter.
  • Over five years, FCF Margin peaked at 129.32% in Q1 2023 and troughed at 18558.95% in Q3 2020.
  • A 5-year average of 2735.15% and a median of 453.73% in 2024 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: plummeted -1739659bps in 2020 and later soared 188979bps in 2021.
  • Year by year, FCF Margin stood at 7142.52% in 2020, then surged by 67bps to 2370.08% in 2021, then skyrocketed by 67bps to 791.34% in 2022, then soared by 87bps to 100.53% in 2023, then crashed by -37bps to 137.33% in 2024.
  • Business Quant data shows FCF Margin for CAPR at 137.33% in Q4 2024, 515.18% in Q3 2024, and 310.94% in Q2 2024.